← Back to headlines
Mesoblast Stock Rises After FDA Clears Ryoncil Study for Duchenne
Mesoblast shares saw gains following the FDA's clearance for a study to test its drug Ryoncil in treating Duchenne muscular dystrophy.
8 Apr, 11:26 — 8 Apr, 11:26
Sources
Showing 1 of 1 sources
